http://www.recercat.cat:80/handle/2072/202564 Tue, 21 May 2013 18:39:49 GMT 2013-05-21T18:39:49Z http://www.recercat.cat:80/bitstream/id/58517/ http://www.recercat.cat:80/handle/2072/202564 http://www.recercat.cat:80/handle/2072/202767 Clinical pharmacokinetics of mycophenolic acid and its metabolites in solid organ transplant recipient Colom Codina, Helena; Lloberas Blanch, Núria; Caldés, Ana; Andreu, Franc; Torras Ambròs, Joan; Oppenheimer Salinas, Federico; Sanchez-Plumed, Jaime; Gentil, Miguel A.; Kuypers, Dirk R.; Brunet i Serra, Mercè; Ekberg, Henrik; Grinyo Boira, Josep M. Mycophenolate mofetil (MMF), an ester prodrug of the immunosuppressant mycophenolic acid (MPA), is widely used for maintenance immunosuppressive therapy and prevention of renal allograft rejection in renal transplant recipients.MPA inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the “de novo” synthesis of purine nucleotides, thus suppressing both T-cell and B-cell proliferation. MPA shows a complex pharmacokinetics with considerable interand intra- patient by between- and within patient variabilities associated to MPA exposure. Several factors may contribute to it. The pharmacokinetic modeling according to the population pharmacokinetic approach with the non-linear mixed effects models has shown to be a powerful tool to describe the relationships between MMF doses and the MPA exposures and also to identify potential predictive patients’ demographic and clinical characteristics for dose tailoring during the post-transplant immunosuppresive treatment.; Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393 http://www.recercat.cat:80/handle/2072/202767